Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy

Current Eye Research

Volumn 37, Issue 5, 2012, Pages 416-420

  Zhou, Jinzi ^a   Wang, Shuhong ^a   Xia, Xiaobo ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CCL2 chemokine (C C motif) ligand 2; Endothelin 1; Inflammatory; Interleukin; Neovascularisation; Proliferative diabetic retinopathy; Tumor necrosis factor

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; ENDOTHELIN 1; HEMOGLOBIN A1C; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; VITRECTOMY; VITREOUS BODY;

AGED; ANGIOGENESIS INDUCING AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VITRECTOMY; VITREOUS BODY;

EID: 84859891447     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.661114     Document Type: Article

References (41)

1. Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med. 2003;96:266-272. (Pubitemid 36714052)
2. Qazi Y, Maddula S, Ambati BK. Mediators of ocular angiogenesis. J Genet. 2009;88:495-515.
3. Mocan MC, Kadayifcilar S, Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can J Ophthalmol. 2006;41:747-752. (Pubitemid 46113030)
4. Petrovic MG, Korosec P, Kosnik M, Hawlina M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2007;143:175-176. (Pubitemid 44917800)
5. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, Varinli S. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2005;13:375-381. (Pubitemid 41702761)
6. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond). 2006;20:1366-1369. (Pubitemid 44921137)
7. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:719-722. (Pubitemid 40805892)
8. Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, et al. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2003;61:93-101. (Pubitemid 37013653)
9. Cicik E, Tekin H, Akar S, Ekmekci OB, Donma O, Koldas L, et al. Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ophthalmic Res. 2003;35:251-255. (Pubitemid 36980794)
10. Elner SG, Strieter R, Bian ZM, Kunkel S, Mokhtarzaden L, Johnson M, et al. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:1597-1601. (Pubitemid 29001955)
11. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045-1053.
12. Abu el Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992;114:731-736.
13. Petrovic MG, Korosec P, Kosnik M, Hawlina M. Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy. Acta Ophthalmol. 2010;88:e311-e316.
14. Shimura M, Yasuda K, Nakazawa T, Abe T, Shiono T, Iida T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1617-1624.
15. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina. 2008;28:817-824.
16. Kawashima M, Shoji J, Nakajima M, Kamura Y, Sato Y. Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy. Jpn J Ophthalmol. 2007;51:100-104. (Pubitemid 46536758)
17. Abu el-Asrar AM, Van Damme J, Put W, Veckeneer M, Dralands L, Billiau A, et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 1997;123:599-606. (Pubitemid 27203280)
18. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina. 1998;18:546-550. (Pubitemid 30387560)
19. Tashimo A, Mitamura Y, Nagai S, Nakamura Y, Ohtsuka K, Mizue Y, et al. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein- 1 in patients with diabetic retinopathy. Diabet Med. 2004;21:1292-1297. (Pubitemid 39620052)
20. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Imamura K, Ishibashi F, et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2010;89:e9-12.
21. Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk-Hojlo M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples. Cytokine. 2010;49:269-274.
22. Roldan-Pallares M, Rollin R, Martinez-Montero JC, Fernandez-Cruz A, Bravo-Llata C, Fernandez-Durango R. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy. Retina. 2007;27:222-235.
23. Patel JI, Saleh GM, Hykin PG, Gregor ZJ, Cree IA. Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye (Lond). 2008;22:223-228. (Pubitemid 351266462)
24. Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T. Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina. 2001;21:647-651. (Pubitemid 34027780)
25. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487. (Pubitemid 24356306)
26. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584. (Pubitemid 24285965)
27. Adamiec-Mroczek J, Oficjalska-Mlynczak J. Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes- role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1665-1670.
28. Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology. 2009;116:921-926.
29. Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today. 1996;2:198-204. (Pubitemid 126401890)
30. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395. (Pubitemid 30208155)
31. Zhu H, Shi CH. Analysis of the diagnostic value of plasma endothelin for diabetic retinopathy using the receiver operating characteristic curve. Ophthalmic Res. 2007;39:289-293.
32. Limb GA, Webster L, Soomro H, Janikoun S, Shilling J. Platelet expression of tumour necrosis factor-alpha (TNFalpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;118:213-218. (Pubitemid 29519250)
33. Rosenbaum JT, Samples JR, Hefeneider SH, Howes EL, Jr. Ocular inflammatory effects of intravitreal interleukin 1. Arch Ophthalmol. 1987;105:1117-1120. (Pubitemid 17136392)
34. Schwartzman ML, Iserovich P, Gotlinger K, Bellner L, Dunn MW, Sartore M, et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes. 2010;59:1780-1788.
35. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736-741. (Pubitemid 26034921)
36. Matsuura A, Yamochi W, Hirata K, Kawashima S, Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension. 1998;32:89-95. (Pubitemid 28324130)
37. Fleisher LN, Ferrell JB, McGahan MC. Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation. 1990;14:325-335. (Pubitemid 20174282)
38. Rosenbaum JT, Howes EL, Jr., Rubin RM, Samples JR. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol. 1988;133:47-53.
39. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280-285. (Pubitemid 46670411)
40. Schalkwijk CG, Chaturvedi N, Twaafhoven H, van Hinsbergh VW, Stehouwer CD. Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest. 2002;32:500-506. (Pubitemid 36223420)
41. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 1995;27:537-541.